VITAMIN-D-3 METABOLISM IN PATIENTS WITH RHEUMATIC DISEASES - LOW SERUM LEVELS OF 25-HYDROXYVITAMIN D-3 IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS

被引：125

作者：

MULLER, K

KRIEGBAUM, NJ

BASLUND, B

SORENSEN, OH

THYMANN, M

BENTZEN, K

机构：

[1] Laboratory for Medical Immunology, Medical Department TTA, Rigshospitalet State University Hospital, Copenhagen, DK-220, Rigshospitalet

[2] Laboratory for Autoimmune Serology, State Serum Institute, Copenhagen

[3] Osteoporosis Research Centre, Copenhagen Municipal Hospital, Copenhagen

[4] Institute of Forensic Genetics, University of Copenhagen, Copenhagen

来源：

CLINICAL RHEUMATOLOGY | 1995年 / 14卷 / 04期

关键词：

1,25-DIHYDROXYVITAMIN D-3; 25-HYDROXYVITAMIN D-3; SYSTEMIC LUPUS ERYTHEMATOSUS; RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; GC-GLOBULIN;

D O I：

10.1007/BF02207671

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1,25-dihydroxyvitamin D-3 (1,25(OH)(2) D-3) has been shown to modulate lymphocyte activation in vitro. Through binding to specific: receptors 1,25-(OH)(2) D-3 inhibits proliferation, immunoglobulin production and the release of cytokines, Moreover, 1,25-(OH)(2) D-3 is efficiently produced by activated monocytes, These findings suggest that 1,25-(OH)(2) D-3 may play a role as a regulator of immunological activation. Consequently, we found it of interest to study the serum levels of the two major metabolites of vitamin D, in patients with systemic lupus erythematosus (SLE) (n=21), rheumatoid arthritis (RA) (n=29) and osteoarthritis (n=12). In patients with SLE the levels of 25-OH D-3 were below those of the healthy controls (p = 0.0008) and OA (p = 0.0168), The levels 1,25-(OH)(2) D-3 corresponded to normal levels. There were no significant correlations between 25-OH D-3 levels and clinical or paraclinical disease manifestations. Further, the phenotypic distribution of Gc-globulin, which binds vitamin D-3 metabolites in circulation, was normal. The serum concentrations of 1,25-(OH)(2) D-3 and 25-OH D-3 in patients with RA and OA corresponded to those of the controls. Although the cause of the reduced 25-OH D-3 levels in SLE patients is unclear, possible beneficial effects of administration of vitamin D to these patients should be considered.

引用

页码：397 / 400

页数：4

共 31 条

[1] Reichel H., Koeffler H.P., Norman A.W., The role of the vitamin D endocrine system in health, N Engl J Med, 320, pp. 980-991, (1989)
[2] Rigby W.F.C., The immunobiology of vitamin D, Immunol Today, 9, pp. 54-58, (1988)
[3] Manolagas S.C., Hustmyer F.G., Yu X.P., Immunomodulating properties of 1,25-dihydroxyvitamin D3, Kidney Int Suppl, 29, pp. 9-16, (1990)
[4] Provvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C., 1,25-Dihydroxyvitamin D3 receptors in human leukocytes, Science, 221, pp. 1181-1182, (1983)
[5] Manolagas S.C., Wernitz D.A., Tsoukas C.D., Provvedini D.M., Vaughan J.H., 1,25-Dihydroxyvitamin D3 receptors in lymphocytes from patients with rheumatoid arthritis, J Lab Clin Med, 108, pp. 596-600, (1986)
[6] Rigby W.F., Stacy T., Fanger M.W., Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol), J Clin Invest, 74, pp. 1451-1455, (1984)
[7] Muller K., Svenson M., Bendtzen K., 1 alpha, 25-dihydroxyvitamin D3 and a novel vitamin D analogue, Immunology Letters, 17, pp. 361-365, (1988)
[8] Lemire J.M., Ada J.S., Sakai R., Jordan S.C., 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells, J Clin Invest, 74, pp. 657-661, (1984)
[9] Iho S., Takahashi T., Kura F., Sugiyama H., Hoshino T., The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production by human B cells, J Immunol, 136, pp. 4427-4431, (1986)
[10] Muller K., Heilmann C., Poulsen L.K., Barington T., Bendtzen K., The role of monocytes and T cells in 1,25 dihydroxyvitamin D3 mediated inhibition of B cell function in vitro, Immunopharmacology, 21, pp. 121-128, (1991)

← 1 2 3 4 →